Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lineage Cell Therapeutics (LCTX) Accumulated Depreciation & Amortization (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Accumulated Depreciation & Amortization data on record, last reported at -$2.3 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 224.73% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached -$2.3 million, down 224.73%, while the annual FY2025 figure was -$2.3 million, 224.73% down from the prior year.
  • Accumulated Depreciation & Amortization reached -$2.3 million in Q4 2025 per LCTX's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $276.0 million in Q2 2023 and bottomed at -$2.3 million in Q4 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $63.0 million, with a median of $2.2 million recorded in 2025.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 86106.9% in 2022, then tumbled 224.73% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $504000.0 in 2021, then grew by 15.48% to $582000.0 in 2022, then surged by 135.22% to $1.4 million in 2023, then soared by 37.33% to $1.9 million in 2024, then crashed by 224.73% to -$2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were -$2.3 million in Q4 2025, $2.6 million in Q3 2025, and $2.4 million in Q2 2025.